Cancer Treatment: Surgery, Radiation, Immunotherapy, and Targeted Therapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Cancer treatment in the contemporary era is a multi-modality, molecularly guided discipline requiring coordinated input from an oncology multidisciplinary team (MDT) — also called a tumour board — comprising medical oncologists, surgical oncologists, radiation oncologists, pathologists, diagnostic radiologists, palliative care specialists, clinical nurse specialists, and allied health professionals (dietitians, physiotherapists, psychologists). The two overarching goals of treatment are curative intent (achieving disease-free survival) and palliative intent (controlling disease, prolonging life, and preserving quality of life when cure is not achievable).

The treatment strategy for any individual patient is determined by: tumour type and site of origin; histological subtype and grade; molecular profile (driver mutations, receptor expression, microsatellite instability, tumour mutational burden); disease stage (TNM classification — T: tumour size/invasion, N: regional nodes, M: distant metastasis); and patient factors — WHO/ECOG Performance Status (PS 0: fully active; PS 1: restricted strenuous activity; PS 2: ambulatory >50% waking hours; PS 3: limited self-care; PS 4: fully disabled), organ function, comorbidities, and patient preferences.

Major advances over the past two decades have transformed outcomes in many cancers: molecular profiling by next-generation sequencing (NGS) identifies targetable driver mutations in >50% of solid tumours; immune checkpoint inhibitors achieve durable multi-year responses in previously lethal cancers (metastatic melanoma, NSCLC, MSI-H colorectal cancer); and CAR-T cell therapy has achieved complete remissions in chemorefractory haematological malignancies. Early integration of palliative care — demonstrated by the landmark Temel et al. NEJM 2010 trial in metastatic NSCLC — improves quality of life and, counter-intuitively, overall survival by 2.7 months compared with standard oncological care alone.

Modern cancer treatment principles apply across all tumour types. The major categories include:

Solid Tumours — Common:

• Lung cancer: NSCLC (adenocarcinoma, squamous cell, large cell) and SCLC — accounts for 18% of cancer deaths globally. Molecular profiling (EGFR, ALK, ROS1, KRAS G12C, MET, RET, NTRK, PD-L1) is mandatory for all non-squamous NSCLC.
• Breast cancer: Hormone receptor-positive (ER+/PR+, ~70%), HER2+ (~15%), triple-negative (TNBC, ~15%). Each subtype has distinct systemic treatment pathways.
• Colorectal cancer (CRC): RAS/BRAF/MSI status guides use of anti-EGFR agents, BRAF inhibitors, and immunotherapy.
• Prostate cancer: Androgen-sensitive and castration-resistant (CRPC) phases; AR-targeted agents (enzalutamide, abiraterone), PARP inhibitors for HRR-mutated CRPC.
• Gastric and gastro-oesophageal junction (GEJ) cancer: HER2+, PD-L1 CPS ≥5, and MSI-H subgroups with distinct targeted/immunotherapy approvals.
• Hepatocellular carcinoma (HCC), pancreatic cancer, ovarian cancer, cervical cancer, bladder cancer, renal cell carcinoma, melanoma, head and neck SCC, glioblastoma.

Haematological Malignancies:

• Acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), chronic myeloid leukaemia (CML — BCR-ABL TKIs have transformed CML from a fatal disease to a manageable chronic condition), chronic lymphocytic leukaemia (CLL).
• Hodgkin lymphoma, non-Hodgkin lymphoma (DLBCL, follicular, mantle cell), multiple myeloma.

Rare Tumours: Soft tissue sarcoma, bone sarcoma (osteosarcoma, Ewing), neuroendocrine tumours (NETs), thyroid carcinoma, adrenocortical carcinoma.

Comprehensive pre-treatment assessment determines eligibility for each treatment modality and guides MDT decision-making:

Performance Status (PS): WHO/ECOG PS is the single most important eligibility criterion for systemic therapy. PS 0-1: eligible for all standard regimens and most clinical trials. PS 2: eligible for selected single-agent or reduced-intensity regimens; benefits must clearly outweigh toxicity risk. PS 3-4: systemic anti-cancer therapy generally inappropriate; best supportive care (BSC) and specialist palliative care are prioritised.

Organ Function:

• Renal (eGFR): cisplatin requires eGFR >60 mL/min; carboplatin dose calculated by Calvert formula using AUC and eGFR.
• Hepatic: bilirubin and AST/ALT — dose reductions or agent substitutions for hepatic impairment. HBV screening mandatory before immunosuppressive chemotherapy (rituximab, steroids) — reactivation risk.
• Cardiac (LVEF): anthracyclines (doxorubicin, epirubicin) and trastuzumab require baseline LVEF ≥50% with 3-monthly monitoring. Cardio-oncology input for borderline cases.
• Pulmonary: pre-thoracic surgery spirometry; FEV1 >40% predicted and predicted post-operative FEV1 >800 mL required for lobectomy.

Molecular and Biomarker Profiling: Comprehensive NGS (tissue or plasma ctDNA) for all advanced/metastatic cancers before initiating systemic therapy. Key biomarkers: EGFR exon 19/21 (NSCLC — osimertinib), ALK/ROS1 (NSCLC — alectinib), PD-L1 TPS/CPS (immunotherapy eligibility), MSI/dMMR (pan-tumour immunotherapy eligibility — pembrolizumab KEYNOTE-158), TMB-H (pembrolizumab in TMB-H solid tumours), HER2 (breast, gastric — trastuzumab+pertuzumab), KRAS G12C (sotorasib, adagrasib), BRAF V600E (dabrafenib+trametinib), BRCA1/2/HRR mutations (PARP inhibitors in ovarian, breast, prostate, pancreatic).

Staging: PET-CT (whole body staging for lymphoma, melanoma, NSCLC, head and neck), contrast CT chest-abdomen-pelvis, MRI brain (NSCLC stage III-IV, melanoma), bone scan (prostate, breast), tumour markers (CA-125, CEA, AFP, PSA, LDH).

1. Surgery: The primary curative modality for localised solid tumours. R0 resection (histologically clear margins) achieves the best oncological outcomes. R1 (microscopically positive margin) and R2 (macroscopically positive margin) are associated with high local recurrence rates; adjuvant radiotherapy or systemic therapy is recommended. Minimally invasive approaches (laparoscopic, robotic-assisted) are now standard for colorectal, gynaecological, urological, and gastric cancers, reducing morbidity and hospital stay. Cytoreductive surgery with HIPEC (hyperthermic intraperitoneal chemotherapy with heated cisplatin or mitomycin C) addresses peritoneal surface malignancy in selected patients.

2. Radiation Therapy (RT): Radiobiological efficacy is quantified by the Biological Effective Dose (BED) formula: BED = nd × [1 + d/(α/β)], where n = number of fractions, d = dose per fraction. Tumour α/β ratio ~10 Gy (rapidly dividing); late-responding normal tissue α/β ~3 Gy. Conventional fractionation: 1.8-2 Gy/fraction over 25-35 fractions (total 45-70 Gy). Stereotactic Body Radiation Therapy (SBRT/SABR): 3-5 high-dose fractions (7-18 Gy/fraction) for early NSCLC (SPACE trial — equivalent to surgical lobectomy in inoperable patients), liver, spine, and prostate cancer. Proton therapy: Bragg peak physics delivers maximum dose at the tumour depth with minimal exit dose — preferred for paediatric solid tumours (reduced integral dose), skull base chordomas, and paraspinal malignancies where sparing adjacent neural structures is critical. Palliative RT: Single 8 Gy fraction is equivalent to multifraction schedules for painful bone metastases (SCORAD trial); 20 Gy/5 fractions for brain metastases (WBRT) or stereotactic radiosurgery (SRS, 15-24 Gy single fraction) for ≤4 brain metastases.

3. Systemic Therapy:

a. Chemotherapy: Cytotoxic agents kill rapidly dividing cells. Cell-cycle phase-specific agents: antimetabolites (5-FU, capecitabine, gemcitabine — S phase), taxanes (paclitaxel, docetaxel — M phase), vinca alkaloids (vincristine — M phase). Non-phase-specific: alkylating agents (cyclophosphamide, ifosfamide), platinum compounds (cisplatin, carboplatin, oxaliplatin — cross-link DNA). Standard regimens: FOLFOX/FOLFIRI (colorectal), AC-T (breast), GemCis (bladder, NSCLC, pancreatic), ABVD (Hodgkin lymphoma), R-CHOP (DLBCL).

b. Targeted Therapy: Osimertinib (3rd-generation EGFR TKI — FLAURA trial: median PFS 18.9 vs 10.2 months vs 1st-gen TKIs; FLAURA2: osimertinib+chemotherapy for EGFR-mutated advanced NSCLC). Alectinib (ALK TKI — ALEX trial: superior PFS vs crizotinib). Trastuzumab+pertuzumab (HER2+ breast/gastric). Dabrafenib+trametinib (BRAF V600E melanoma, NSCLC, CRC). Sotorasib/adagrasib (KRAS G12C — first approved targets for a 'undruggable' oncogene). Olaparib (PARP inhibitor — BRCA-mutated ovarian, breast, prostate, pancreatic cancer).

c. Immunotherapy — Checkpoint Inhibitors (ICI): Anti-PD-1 (pembrolizumab, nivolumab), anti-PD-L1 (atezolizumab, durvalumab), anti-CTLA-4 (ipilimumab). Pembrolizumab approved as first-line monotherapy for PD-L1 TPS ≥50% NSCLC (KEYNOTE-024 — OS benefit: 26.3 vs 14.2 months vs chemotherapy), TMB-H solid tumours (KEYNOTE-158), and MSI-H/dMMR solid tumours across all histologies (tissue-agnostic approval). Ipilimumab+nivolumab for MSI-H CRC (CheckMate 142) and HCC (CheckMate 9DW). Durvalumab consolidation post-chemoradiation in stage III NSCLC (PACIFIC trial — 5-year OS 42.9% vs 33.4%).

d. Antibody-Drug Conjugates (ADC): Trastuzumab deruxtecan (T-DXd, Enhertu) — DESTINY-Breast01/03/04 trials — HER2+ breast cancer (3rd-line+) and HER2-low breast cancer (IHC 1+ or 2+/FISH-); sacituzumab govitecan (TROP-2 targeting — triple-negative breast cancer, urothelial cancer); enfortumab vedotin (Nectin-4 targeting — bladder cancer); loncastuximab tesirine (CD19, DLBCL).

e. CAR-T Cell Therapy: Tisagenlecleucel (Kymriah — CD19 targeting, B-cell ALL <25 years; DLBCL 3rd-line+), axicabtagene ciloleucel (Yescarta — DLBCL 2nd-line+ per ZUMA-7), ciltacabtagene autoleucel and idecabtagene vicleucel (BCMA targeting — multiple myeloma). Complete remission rates of 50-80% in chemorefractory settings. Key toxicities: cytokine release syndrome (CRS — managed with tocilizumab) and immune effector cell-associated neurotoxicity syndrome (ICANS).

f. Endocrine Therapy: Aromatase inhibitors (letrozole, anastrozole, exemestane) + CDK4/6 inhibitors (palbociclib+letrozole — PALOMA-2: PFS 27.6 vs 14.5 months) for HR+/HER2- breast cancer. Tamoxifen for premenopausal women. ADT (LHRH agonist) + abiraterone or enzalutamide for metastatic prostate cancer.

Contemporary oncological treatment has transformed cancer from a uniformly fatal disease into a curable or chronically manageable condition for a growing proportion of patients:

• Curative potential: Surgery and definitive radiation achieve cure in the majority of early-stage solid tumours. 5-year survival for stage I NSCLC after resection is 80-90%; stage I breast cancer >95%; stage I colorectal cancer >90%. Curative chemoradiation (without surgery) achieves organ preservation for head and neck cancer, early anal canal cancer, and muscle-invasive bladder cancer.
• Dramatically improved survival with targeted therapy and immunotherapy: Median OS for EGFR-mutated metastatic NSCLC has improved from 12 months (chemotherapy) to >38 months with osimertinib+chemotherapy (FLAURA2). Pembrolizumab in MSI-H metastatic CRC achieves 5-year PFS rates of 43% (KEYNOTE-177). Metastatic melanoma 5-year survival has risen from 5% to >50% with combined ipilimumab+nivolumab (CheckMate 067).
• Durable complete responses with immunotherapy: A subset of checkpoint inhibitor responders achieve multi-year durable remissions, with ongoing responses even after treatment discontinuation — the 'tail of the survival curve' phenomenon that does not occur with chemotherapy.
• CAR-T — complete responses in refractory haematological malignancies: In B-cell ALL children with disease refractory to >2 prior lines, tisagenlecleucel achieves complete remission in ~80%, with some patients cured — outcomes previously unachievable.
• Quality of life improvements: Minimally invasive surgery (laparoscopic, robotic), hypofractionated radiation, and oral targeted therapies reduce treatment burden and hospitalisation, enabling patients to maintain daily activities and employment.
• Early palliative care integration: Temel et al. (NEJM 2010) demonstrated that early palliative care in metastatic NSCLC patients improved median OS by 2.7 months, reduced aggressive end-of-life interventions, and improved patient-reported quality of life — now an ASCO/ESMO guideline recommendation for all patients with advanced cancer.

All cancer treatment modalities carry risks that must be weighed against expected benefits in individual patients:

Chemotherapy toxicities:

• Myelosuppression: Neutropenia, anaemia, thrombocytopenia. Febrile neutropenia (FN) risk stratified by regimen — high-risk regimens (FN >20%) mandate primary GCSF prophylaxis (filgrastim, pegfilgrastim) per ASCO/EORTC guidelines.
• Peripheral neuropathy: Platinum compounds (oxaliplatin — dose-limiting cumulative sensory neuropathy) and taxanes (paclitaxel — sensory/motor). Often dose-limiting and may persist after treatment completion.
• Nephrotoxicity: Cisplatin — prevented by aggressive IV hydration; aminoglycosides synergistically nephrotoxic.
• Alopecia, mucositis, nausea/vomiting — managed with 5-HT3 antagonists (ondansetron), NK1 antagonists (aprepitant), and scalp cooling.

Immunotherapy — Immune-related Adverse Events (irAE):

• Pneumonitis (3-5% — most serious; managed with prednisolone 1-2 mg/kg/day, hold ICI).
• Colitis (diarrhoea, bowel perforation — anti-CTLA-4 > anti-PD-1; managed with steroids ± infliximab).
• Hepatitis (transaminase elevation — steroids ± mycophenolate mofetil).
• Endocrinopathies: hypothyroidism (10-20% — levothyroxine replacement), hypophysitis (rare — hydrocortisone + levothyroxine replacement), adrenal insufficiency (rare — hydrocortisone replacement, permanent).
• Dermatitis, nephritis, myocarditis (rare but potentially fatal; ECG and troponin monitoring in high-risk patients).

Targeted therapy — class-specific toxicities: EGFR TKIs (acneiform rash, diarrhoea, osimertinib-specific: cardiomyopathy, QTc prolongation); ALK TKIs (visual disturbance, bradycardia — alectinib); BCR-ABL TKIs (fluid retention, QTc, pleural effusion); VEGFR inhibitors (hypertension, proteinuria, wound healing impairment).

Radiation toxicities: Acute (during treatment): mucositis, radiation dermatitis, dysphagia, diarrhoea, fatigue. Late (months-years post-RT): radiation fibrosis, lymphoedema, secondary malignancy (risk 1-2% over 10 years for modern techniques), radiation pneumonitis (1-3% with modern lung RT).

CAR-T specific: CRS (fever, hypotension, hypoxia — Grade 3-4 in 20-30%: tocilizumab 8 mg/kg IV); ICANS (confusion, aphasia, seizures — managed with corticosteroids); prolonged cytopenias; B-cell aplasia and hypogammaglobulinaemia requiring IVIG replacement.

Oncological follow-up after active treatment serves three purposes: early detection of disease recurrence or progression; monitoring and managing late treatment toxicities; and supporting long-term survivorship.

Disease surveillance (selected examples by cancer type):

• NSCLC: CT chest ± abdomen every 3-6 months for 2 years, then annually to 5 years; brain MRI for stage III-IV patients.
• Breast cancer: Annual mammography (contralateral breast); ECHO monitoring for anthracycline/trastuzumab recipients (baseline, 3-monthly during treatment, 6-monthly × 2 years post); bone density DEXA for aromatase inhibitor recipients.
• Colorectal cancer: CT chest-abdomen-pelvis 6-monthly × 2 years, then annually × 3 years; colonoscopy at 1 year and 5 years; CEA every 3-6 months × 3 years.
• Prostate cancer: PSA every 3-6 months during active treatment; PSA doubling time at recurrence guides salvage strategy.

Long-term toxicity monitoring: Cardiotoxicity (ECHO or MUGA scan annually for 5 years for anthracycline recipients; earlier if symptoms); peripheral neuropathy assessment; bone health (bisphosphonate/denosumab therapy for patients on aromatase inhibitors or ADT); cognitive effects ('chemo brain'); fertility preservation (sperm banking, embryo cryopreservation before gonadotoxic chemotherapy in young patients).

Survivorship plan: All patients completing curative-intent treatment should receive a formal survivorship care plan addressing: return to work, physical activity prescription (reduces recurrence risk in breast and CRC), sexual health, psychological support (anxiety, depression, PTSD prevalent in cancer survivors), and patient-reported outcome monitoring.

Clinical trial participation: Participation in clinical trials at disease progression is strongly encouraged — provides access to novel agents and contributes to evidence generation. Search at ClinicalTrials.gov by tumour type and prior treatment lines.

Cancer treatment costs vary enormously by treatment modality, number of cycles, drug costs, and geographic location. Medical tourism for cancer treatment is highly relevant, with savings of 60-85% available in India, Thailand, Turkey, and Malaysia compared to the USA or Australia:

• Surgery (major resection — e.g., lung lobectomy, Whipple, colectomy):
  • India: USD 5,000-15,000 all-inclusive
  • Thailand: USD 8,000-20,000
  • USA: USD 40,000-120,000
• Radiation therapy (curative course, 25-35 fractions, IMRT):
  • India: USD 3,000-8,000
  • Thailand/Turkey: USD 5,000-12,000
  • USA: USD 30,000-80,000
  • Proton therapy: USD 15,000-25,000 (India, limited centres) vs USD 80,000-150,000 (USA)
• Chemotherapy (per cycle, excluding drug acquisition cost):
  • Administration and monitoring: USD 100-500 (India) vs USD 1,000-5,000 (USA)
• Immunotherapy drugs (monthly treatment cost, approximate):
  • Pembrolizumab 200mg Q3W: USD 12,000-18,000/month (USA); USD 1,500-4,000 (India, generic pembrolizumab available); significantly lower in India with domestic biosimilar approvals
  • Nivolumab: USD 10,000-15,000/month (USA)
• Targeted therapy (monthly):
  • Osimertinib 80mg daily: USD 12,000-17,000/month (USA); USD 3,000-6,000 (India brand); generic available in India USD 300-800/month
  • Imatinib (CML): originator USD 10,000/month (USA); generic USD 50-200/month (India)
• CAR-T cell therapy: USD 350,000-500,000 per infusion in USA; USD 80,000-150,000 at specialist centres in India (limited availability).
• Supportive medications: GCSF (pegfilgrastim USD 4,000/dose USA; USD 150-400 India); denosumab USD 2,000/month (USA) vs USD 200-400 (India); bisphosphonates significantly cheaper.

Several alternative or complementary strategies are considered within the cancer treatment framework:

1. Clinical Trials: Enrolment in a well-designed randomised controlled trial (RCT) is considered the gold standard option at disease progression. Clinical trials provide access to investigational agents (often at no drug cost), contribute to evidence generation, and are the mechanism by which novel treatments (immunotherapy, targeted agents, ADCs) reach approval. IND (Investigational New Drug) applications and phase I-III trial design govern progression from first-in-human dose escalation to registration studies. Search ClinicalTrials.gov or ISRCTN for open trials by tumour type, prior treatment, and biomarker status.

2. Active Surveillance / Watchful Waiting: Appropriate for low-risk, indolent cancers where the risks of immediate treatment outweigh benefit. Examples: ISUP Grade 1 prostate cancer (Gleason 3+3 = 6) — active surveillance with PSA monitoring and serial biopsy defers treatment in 50% of men at 10 years. CLL (Binet stage A, Rai stage 0-I) — observation until meeting IWCLL treatment criteria (progressive cytopenias, B symptoms, bulky lymphadenopathy). Follicular lymphoma Grade 1-2, low tumour burden — GELF criteria used to define treatment indication.

3. Best Supportive Care (BSC): For patients with poor performance status (PS 3-4) or advanced comorbidities where systemic anti-cancer therapy is unlikely to provide meaningful benefit and significant toxicity risk. BSC focuses on symptom control — pain (WHO analgesic ladder), breathlessness (opioids, low-dose dexamethasone), nausea (haloperidol, cyclizine), delirium, and family/caregiver support. Integration with specialist palliative care or hospice services.

4. Hospice and Specialist Palliative Care: Not an 'alternative' to cancer treatment but an essential complementary service. Early integration (from diagnosis in metastatic cancer) improves QoL, reduces hospitalisation at end of life, and modestly improves survival (Temel 2010). ASCO and ESMO recommend palliative care referral for all patients with metastatic solid tumours at the time of diagnosis, irrespective of the intent of anti-cancer therapy.

5. Integrative Oncology: Evidence-based complementary approaches — exercise oncology (aerobic + resistance training reduces fatigue and improves OS in CRC and breast cancer), acupuncture for chemotherapy-induced nausea, mindfulness-based stress reduction (MBSR) for anxiety and QoL, and dietary counselling. Patients should be advised to disclose all supplements (St. John's Wort, high-dose antioxidants) as these may interfere with chemotherapy or targeted agents.